

WOAH Reference Laboratory Reports Activities 2024

This report has been submitted: 9 janvier 2025 12:13

LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Turkey rhinotracheitis
*Address of laboratory:	41 route de Beaucemaine - BP53 - 22440 - Ploufragan - France
*Tel:	+33 (0)2 96 01 62 22
*E-mail address:	nicolas.eterradossi@anses.fr
Website:	https://www.anses.fr/fr/portails/1807/content/150764
*Name (including Title) of Head of Laboratory (Responsible Official):	Dr Nicolas Eterradossi
*Name (including Title and Position) of WOAH Reference Expert:	Dr Nicolas Eterradossi, Head of laboratory
*Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
ELISA	Yes	3611	0

Nicolas Eterradosi - - FRANCE

Direct diagnostic tests		Nationally	Internationally
Viral isolation and propagation	Yes	3	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA?H Member Countries	Country of recipients
Viral antigen	ELISA	Produced and provided	14 ml	0	1	FRANCE,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA?H Member?

Yes

Name of the WOA?H Member Country receiving a technical consultancy	Purpose	How the advice was provided
CANADA	Consultation on field cases that occurred in 2024 and difficulties observed with a commercial kit for AMPV diagnostic	Email

Nicolas Eterradossi - - FRANCE

FRANCE	Clinical aspects of AMPV infections in dicks	Email and visioconference
--------	--	---------------------------

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAH Member Countries involved other than your country
Confirmatory diagnosis of AMPV infection in North America	Ongoing	Antigenic analysis of current AMPV strains in North America	Ongoing contacts with veterinary faculties for sample recruitment	CANADA UNITED STATES OF AMERICA

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHP?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
serological data linked with AMPV situation on the North American continent

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

0

c) National conferences:

1

Courtillon et al. (2024) A five-plex digital droplet RT-PCR method for identification of subgroups A, B, C, and D". Seminar on digital PCR

and its applications, Maisons Alfort Alfort, France, Dec 2024.

d) Other (Provide website address or link to appropriate information):

0

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	scan of certificate provided	Compliance certificate ISO 17025 2023-2024.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Avian Influenza an Newcastle disease serological, virological and molecular diagnosis	COFRAC (French Committee for Accreditation)

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory quality management system and procedures comply with nationally applicable regulations and cover biorisk (biosafety and biosecurity) evaluation and management, in line with recommendations of chapter 1.1.4 of OIE Manual

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOA Reference Laboratory designated for the disease)

24. Do you network (collaborate or share information) with other WOA Reference Laboratories designated for the same pathogen?

Not applicable (only WOA Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen during the past 2 years?

Not applicable (Only WOA Reference Laboratory designated for the disease)

Not applicable

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (only WOA Reference Laboratory designated for the disease)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAH Member Countries
Serological detection of anti-TRTV antibodies	Participant	25	ELISA	AUSTRALIA, AUSTRIA, COLOMBIA, FRANCE, GERMANY, HUNGARY, ISRAEL, JORDAN, KAZAKHSTAN, MALAYSIA, NAMIBIA, THE NETHERLANDS, TURKEY, UNITED KINGDOM, UNITED STATES OF AMERICA, ZIMBABWE,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

Yes

Kind of consultancy	Location	Subject (facultative)
TRTV case definition	online	finalization of discussions re case-definition, confirmatory diagnosis and target host species

29. Additional comments regarding your report:

Yes

Human resource issues in WOA TRT reference laboratory (two senior scientists missing) continued in 2024, as recruitment procedures initiated in 2024 were unsuccessful and are still ongoing. A letter was sent to explain this situation upon WOA request.